Barinthus Biotherapeutics PLC is a publicly traded company operating in the Biotechnology industry, headquartered in GB. Its shares trade on NASDAQ NMS - GLOBAL MARKET under the ticker BRNS, with a market capitalization of approximately $25 million. A full business summary isn’t available for this company yet — the fig…
An institutional-grade, numbers-driven thesis on BRNS — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates Barinthus Biotherapeutics PLC (BRNS) 61/100 with a 12-month base-case forecast of $0.44 — -29.0% versus the current price of $0.62. Barinthus Biotherapeutics PLC trades at $0.62 in the Biotechnology sector, with a market capitalisation of $25.3M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for BRNS is $0.44, implying -29.0% versus the current price. The model's 12-month scenario range runs from $0.41 (bear) to $0.52 (bull), with a base case of $0.44.
On the fundamentals, Barinthus Biotherapeutics shows trailing revenue of $0. This page also tracks BRNS's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
BRNS currently carries a TradersQuant composite score of 61/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "buy". Our 12-month price target of $0.44 implies -29.0% from $0.62. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for BRNS is $0.44, about -29.0% versus the latest price of $0.62. Consensus is based on 8 analysts.
TradersQuant's 12-month model forecast for BRNS is a base case of $0.44, ranging from $0.41 (bear) to $0.52 (bull), an expected return of -28.5%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for BRNS over the next 12 months is $0.44 in the base case (bear $0.41, bull $0.52), versus today's price of $0.62. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for BRNS — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates BRNS's fair value at $0.81, implying +30.3% of expected upside versus the current price.
Barinthus Biotherapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
